
Studies on EGFR mutants in NSCLC
Hossein Borghaei

What is durvalumab’s future as a treatment option in lung cancer?
Luis Paz-Ares

ASCEND-1 and ASCEND-2: Ceritinib for ALK-rearranged NSCLC and baseline brain metastases
Giorgio Scagliotti

Durvalumab: the new standard of care for NSCLC?
Johan Vansteenkiste

Pembrolizumab and the significance of PD-L1 for lung cancer
Roy Herbst